Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

May 31, 2009

Conditions
Renal ImpairmentDiabetes
Interventions
DRUG

Vildagliptin

Mild, moderate and severe renal impaired patients receiving 25 mg vildagliptin once daily

DRUG

Vildagliptin

Mild, moderate and severe renal impaired patients receiving 50 mg vildagliptin once daily

DRUG

Vildagliptin

Matching healthy volunteers receiving 25 mg vildagliptin once daily.

DRUG

Vildagliptin

Matching healthy volunteers receiving 50 mg vildagliptin once daily

Trial Locations (1)

Unknown

Novartis Investigator Site, Moscow

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY